Principal Investigator(s):

Mark Utell, Mark Frampton

Summary:

Project Update (215kb .pdf)

There are significant concerns about the adverse health effects of fine particles (PM_2.5) in ambient air. One proposed hypothesis is that the number of ultrafine particles (UFPs), which contribute very little to total PM_2.5 mass concentrations in ambient air, may be responsible for these effects.

This project conducted clinical studies of exposure to UFPs in healthy human subjects, developing an exposure system for carbon UFPs and a clinical protocol incorporating measurements of particle deposition. The research team found that UFP exposure, even at very low-mass concentrations, may have negative effects on vascular and cardiac functioning in healthy subjects. Women and individuals engaging in exercise may be more susceptible to these effects.

Partners:

Downloads:

Final report (351kb.pdf)

Executive Summary (74kb .pdf)

Project Update (215kb .pdf)

Project Site(s):

Rochester

Latitude/Longitude: (4kb .pdf)

Region(s): Western

County(ies): Monroe

Sampling:

Sampled Medium(Media): air

Analyte(s): ultrafine particles

Sampling Technolog(ies):

Sampling Frequency:

Funding:

Total Costs: $817,141

NYSERDA Costs: $480,851

Funding Source(s): NYSERDA, University of Rochester Medical Center

Contract Initiated: February, 1999

Estimated Completion Date:

Links:

Project Website: http://www2.envmed.rochester.edu/envmed/TOX/faculty/utell.html

Related EMEP Projects: Philip Hopke 6820, Philip Hopke 7607, Daniel Luttinger 6484

Contact:

Mark Utell, M.D.
University of Rochester Medical Center
601 Elmwood Avenue, Box 692
Rochester, New York 14642
PH: (585) 275-4861
Fax: (585) 273-1058
Email: mark_utell@urmc.rochester.edu

Mark Frampton, MD
University of Rochester Medical Center
601 Elmwood Ave., Box 692
Rochester, New York 14642
PH: (585) 275-4861
Fax: (585) 273-1058
Email: mark_frampton@urmc.rochester.edu